FDA Clears Quantum BioPharma's Lucid-MS for Phase 2 Trial, Advancing a Non-Immunosuppressive Approach to Multiple Sclerosis

Quantum BioPharma has received FDA clearance to begin Phase 2 testing of Lucid-MS, a first-in-class multiple sclerosis candidate that aims to protect myelin rather than suppress the immune system, potentially offering a safer and more targeted treatment option.

Chicago Metrowire Staff
••Healthcare
FDA Clears Quantum BioPharma's Lucid-MS for Phase 2 Trial, Advancing a Non-Immunosuppressive Approach to Multiple Sclerosis

Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, has secured U.S. Food and Drug Administration approval of its Investigational New Drug application for Lucid-MS, its lead candidate for multiple sclerosis. The clearance allows the company to proceed with a Phase 2 randomized, double-blind, placebo-controlled study to evaluate the drug's efficacy, safety, and tolerability in patients with MS. Researchers will assess clinical symptoms and changes visible through brain imaging, according to the company's announcement.

The significance of this milestone lies in Lucid-MS's distinct mechanism of action. Unlike most existing MS therapies that target the immune system, Lucid-MS is designed to protect nerve cells by inhibiting PAD2, an enzyme associated with myelin damage. This non-immunosuppressive approach could potentially offer a safer alternative for patients who cannot tolerate or do not respond adequately to current treatments. By focusing on myelin protection rather than immune suppression, Quantum BioPharma is pursuing a strategy that may address the underlying cause of disability in MS rather than merely managing symptoms.

Lucid-MS previously completed Phase 1 trials in healthy volunteers, where the company reported a favorable safety profile and good tolerability. This foundation supports advancing the compound into a larger patient population. If successful, Lucid-MS could become a first-in-class therapy for MS, a chronic disease that affects millions worldwide and often leads to progressive disability. The FDA's acceptance of the IND application reflects the agency's recognition of the need for new therapeutic options in this space.

Quantum BioPharma, through its wholly owned subsidiary Lucid Psycheceuticals Inc., focuses on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company's broader portfolio includes assets targeting neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. In addition to its pharmaceutical pipeline, Quantum invented UNBUZZD(TM) and spun out its over-the-counter version to Unbuzzd Wellness Inc., retaining a 19.48% ownership stake and royalty rights. For more details on Quantum's work, visit Quantum BioPharma (NASDAQ: QNTM).

Investors and industry observers can stay updated on QNTM's progress through the company's newsroom at https://ibn.fm/QNTM. The full article on this development is available at https://ibn.fm/g5EXE. This news is particularly important because it marks a potential paradigm shift in MS treatment, moving beyond immunosuppression to direct neuroprotection. If Lucid-MS proves effective in Phase 2, it could provide a much-needed option for patients with progressive forms of MS, for whom current therapies are often limited.

The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which offers a suite of services including wire distribution via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution. For more information, visit BioMedWire.

Blockchain Registration

QR Code for Blockchain Registration